Bagley Jessamyn, Paez-Cortez Jesus, Tian Chaorui, Iacomini John
Transplantation Research Center, Renal Division, Brigham and Women's Hospital and Children's Hospital Boston, Harvard Medical School, Boston, MA 02115, USA.
Crit Rev Immunol. 2008;28(4):301-24. doi: 10.1615/critrevimmunol.v28.i4.30.
Type 1 diabetes (T1D) is caused by the autoimmune-mediated destruction of insulin-producing beta cells in the pancreas. T1D affects as many as 3 million patients in the United States alone, with 15,000 new cases developing every year (Juvenile Diabetes Research Foundation), and presently there is no cure for T1D. In recent years, there has been a great deal of interest in developing gene therapy approaches to treat T1D. Gene therapy approaches tend to fall into three broad categoriesthose aimed at preventing or curing autoimmunity, those aimed at restoring insulin production through islet transplant or genetically engineered insulin production, and approaches that aim to prevent the morbidity and mortality associated with this complex disease. We review these studies here.
1型糖尿病(T1D)是由自身免疫介导的胰腺中产生胰岛素的β细胞破坏所致。仅在美国,T1D就影响着多达300万患者,每年有15000例新发病例(青少年糖尿病研究基金会),目前T1D无法治愈。近年来,人们对开发治疗T1D的基因治疗方法产生了浓厚兴趣。基因治疗方法大致可分为三大类:旨在预防或治愈自身免疫的方法、旨在通过胰岛移植或基因工程胰岛素生产恢复胰岛素分泌的方法,以及旨在预防与这种复杂疾病相关的发病率和死亡率的方法。我们在此对这些研究进行综述。